CYP2E1 activity in patients with alcoholic liver disease

Journal of Hepatology

Volumn 27, Issue 6, 1997, Pages 1009-1014

  Dilger, Karin ^a   Metzler, Jörg ^b   Bode, Johann Christian ^b   Klotz, Ulrich ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

Alcoholic liver disease; Chlorzoxazone; Cytochrome P450

Indexed keywords

6 HYDROXYCHLORZOXAZONE; ALCOHOL; CHLORZOXAZONE; CYTOCHROME P450; DRUG METABOLITE; UNCLASSIFIED DRUG;

ADULT; AGED; ALCOHOL ABUSE; ALCOHOL BLOOD LEVEL; ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HUMAN; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0030832859     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80144-4     Document Type: Article

References (43)

1. Lelbach WK. Cirrhosis in the alcoholic and its relation to the volume of alcohol abuse. Ann NY Acad. 252:1975;85-105.
2. Lumeng L, Crabb DW. Genetic aspects and risk factors in alcoholism and alcoholic liver disease. Gastroenterology. 107:1994;572-578.
3. Morimoto M, Hagbjoerk AL, Nanji A, Ingelman-Sundberg M, Lindros KO, Fu PC, et al. Role of cytochrome P4502E1 in alcoholic liver disease pathogenesis. Alcohol. 10:1993;459-464.
4. Maezawa Y, Yamauchi M, Toda G. Association between restriction fragment length polymorphism of the human cytochrome P450IIEI gene and susceptibility to alcoholic liver cirrhosis. Am J Gastroenterol. 89:1994;561-565.
5. Tsutsumi M, Takada A, Wang JS. Genetic polymorphisms of cytochrome P4502E1 related to the development of alcoholic liver disease. Gastroenterology. 107:1994;1430-1435.
6. Lieber CS. Hepatic and metabolic effects of ethanol: pathogenesis and prevention. Ann Med. 26:1994;325-330.
7. Koop DR, Cederbaum AI, Song BJ, Ingelman-Sundberg M, Nanji A. Ethanol-inducible cytochrome P450 (CYP2E1): biochemistry, molecular biology and clinical relevance: 1996 update. Alcohol Clin Exp Res. 20:1996;138A-143A.
8. Koop DR. Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB. 6:1992;724-730.
9. Murray M. P450 enzymes: inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet. 23:1992;132-146.
10. Lucas C, Menez C, Girre C, Bodenez P, Hispard E, Menez JF. Decrease in cytochrome P4502E1 as assessed by the rate of chlorzoxazone hydroxylation in alcoholics during the withdrawal phase. Alcohol Clin Exp Res. 19:1995;362-366.
11. Kim RB, O'Shea D, Wilkinson GR. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther. 57:1995;645-655.
12. Bachmann K, Sarver JG. Chlorzoxazone as a single sample probe of hepatic CYP2E1 activity in humans. Pharmacology. 52:1996;169-177.
13. Peter R, Boecker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol. 3:1990;566-573.
14. George J, Murray M, Byth K, Farrell G. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology. 21:1995;120-128.
15. Guengerich FP, Turvy CG. Comparison of levels of several human microsomal cytochrome P-450 enzymes und epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther. 256:1991;1189-1194.
16. Lown K, Kolars J, Turgeon K, Merion R, Wrighton SA, Watkins PB. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther. 51:1992;229-238.
17. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 60:1973;646-649.
18. Girre C, Lucas D, Hispard E, Menez C, Dally S, Menez JF. Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem Pharmacol. 47:1994;1503-1508.
19. Lucas D, Menez C, Girre C, Bodenez P, Hispard E, Menez JF. Decrease in cytochrome P4502E1 as assessed by the rate of chlorzoxazone hydroxylation in alcoholics during withdrawal phase. Alcohol Clin Exp Res. 19:1995;362-366.
20. Song BJ, Matsunaga T, Hartwick JP, Park SS, Veech RL, Yang CS, et al. Stabilization of cytochrome P450j messenger ribonucleic acid in the diabetic rat. Mol Endocrinol. 1:1987;542-547.
21. Dong Z, Hong J, Ma Q. Mechanism of induction of cytochrome P-450ac (P-450j) in chemically induced and spontaneously diabetic rats. Arch Biochem Biophys. 263:1988;29-35.
22. O'Shea D, Davis SN, Kim RB, Wilkinson GR. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther. 56:1994;359-367.
23. Lucas D, Menez C, Girre C, Berthou F, Bodenez P, Joannet I, et al. Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Pharmacogenetics. 5:1995;298-304.
24. Carriere V, Goasduff T, Ratanasavanh D, Morel F, Gautier JC, Guillouzo A, et al. Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone. Chem Res Toxicol. 6:1993;852-857.
25. Yamazaki H, Guo Z, Guengerich FP. Selectivity of cytochrome P4502E1 in chlorzoxazone 6-hydroxylation. Drug Metab Dispos. 23:1995;438-439.
26. Berthou F, Goasduff T, Lucas D, Dreano Y, Le Bot MH, Menez JF. Interaction between two probes used for phenotyping cytochromes P4501A2 (caffeine) and P4502E1 (chlorzoxazone) in humans. Pharmacogenetics. 5:1995;72-79.
27. Ono S, Hatanaka T, Hotta H, Tsutsui M, Satoh T, Gonzalez FJ. Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics. 5:1995;143-150.
28. Carriere V, Berthou F, Baird S, Belloc C, Beaune P, de Waziers I. Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype. Pharmacogenetics. 6:1996;203-211.
29. McCarver-May DG, Durisin L. Human hepatic alcohol dehydrogenase and human erythrocyte catalase do not metabolize the cytochrome P-4502E1 substrate, chlorzoxazone. Alcohol Clin Exp Res. 20:1996;533-537.
30. Denaro CP, Wilson M, Jacob P III, Benowitz NL. The effect of liver disease on urine caffeine metabolite ratios. Clin Pharmacol Ther. 59:1996;624-635.
31. Rost KL, Brockmöller J, Esdorn F, Roots I. Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment. J Hepatol. 23:1995;268-277.
32. Leeder JS, Okey AB. Cytochromes P450 and liver injury. Cameron RG, Feuer G, Delaiglesia FA. Drug-Induced Hepatoxicity. 1996;119-153 Springer-Verlag, Berlin.
33. Kharasch ED, Hankins D, Mautz D, Thummel KE. Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. Lancet. 347:1996;1367.
34. Lee SST, Buters JTM, Pineau T, Fernandez-Salguero P, Gonzalez FJ. Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem. 271:1996;12063-12067.
35. Nightingale SL. From the Food and Drug Administration: chlorzoxazone warning on hepatoxicity is strengthened. JAMA. 24:1995;1903.
36. Pequinot G, Tuynus AJ, Berta JL. Ascitic cirrhosis in relation to alcohol consumption. Int J Epidemiol. 7:1978;113-120.
37. Stephens EA, Taylor JA, Kaplan N, Yang CH, Hsieh LL, Lucier GW, et al. Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics. 4:1994;185-192.
38. Kim RB, Yamazaki H, Chiba K, O'Shea D, Mimura M, Guengerich FP, et al. In vivo and in vitro characterized of CYP2E1 activity in Japanese and Caucasians. J Pharmacol Exp Ther. 279:1996;4-11.
39. Carr LG, Hartleroad JY, Liang Y, Mendenhall C, Moritz T, Thomasson H. Polymorphism at the P450IIE1 locus is not associated with alcoholic liver disease in Caucasian men. Alcohol Clin Exp Res. 19:1995;182-184.
40. Lucas D, Menez C, Floch F, Gourlaouen Y, Sparfel O, Joannet I, et al. Cytochromes P4502E1 and P4501A1 genotypes and susceptibility to cirrhosis or upper aerodigestive tract cancer in alcoholic Caucasians. Alcohol Clin Exp Res. 20:1996;1033-1037.
41. Savoleinen VT, Pajarinen J, Perola M, Pentilä A, Karhunen PJ. Polymorphism in the cytochrome P450 2E1 gene and the risk of alcoholic liver disease. J Hepatol. 26:1997;55-61.
42. Agundez J, Ladero J, Diaz-Rubio M, Benitz J. Rsa I polymorphism at the cytochrome P4502E1 locus is not related to the risk of alcoho-related severe liver disease. Liver. 16:1996;380-383.
43. Pirmohamed M, Kitteringham NR, Quest LJ, Allott RL, Green VJ, Gilmore IT, et al. Genetic polymorphism of cytochrome P4502E1 and risk of alcoholic liver disease in Caucasians. Pharmacogenetics. 5:1995;351-357.